Olivier Loeillot, Chief Executive Officer and Director of Repligen Corp (NASDAQ:RGEN), filed a Form 4 on August 21, 2026, disclosing the exercise of stock options and the sale of 5,426 shares of common stock on August 20, 2026.

Key Highlights

  • Option exercise: Loeillot exercised 5,426 stock options at a conversion price of $141.79 per share on August 20, 2026.
  • Shares sold: 5,426 shares of common stock were disposed of at $180 per share on August 20, 2026.
  • Remaining ownership: Following the transactions, Loeillot directly beneficially owned 54,246 shares of common stock.
  • 10b5-1 plan: According to the filing, the sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Loeillot on August 19, 2025.
  • Remaining options: Loeillot holds 10,852 stock options with an exercise price of $141.79 and an expiration date of September 3, 2034, with 5,426 shares vesting on each of September 3, 2026, and September 3, 2027, according to the filing.

Repligen CEO Option Exercise and Share Sale Details

According to the Form 4 filed with the SEC on August 21, 2026, Olivier Loeillot, who serves as Chief Executive Officer and Director of Repligen Corp, executed two transactions on August 20, 2026. The filing indicates that Loeillot first acquired 5,426 shares of common stock through the exercise of stock options at a price of $141.79 per share, bringing his directly held beneficial ownership to 59,672 shares following that transaction.

In a simultaneous disposition reported in the same filing, Loeillot sold all 5,426 of those shares at $180 per share, reducing his direct beneficial ownership to 54,246 shares. The filing states that the transactions were carried out under a Rule 10b5-1 trading plan that Loeillot adopted on August 19, 2025. The Form 4 was signed by Jennifer Carmichael as Attorney in Fact on August 21, 2026.

The filing also discloses that Loeillot retains 10,852 stock options, each with a conversion price of $141.79 and an expiration date of September 3, 2034. As noted in the filing's explanation of responses, 5,426 of those options will vest on September 3, 2026, and a further 5,426 will vest on September 3, 2027. All reported positions are held directly.

What Was Disclosed

Repligen Corp's CEO Olivier Loeillot disclosed the exercise of 5,426 stock options at $141.79 and the same-day sale of 5,426 common shares at $180, executed under a pre-established Rule 10b5-1 plan, leaving him with 54,246 directly held shares.